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L E T T E R  T O  T H E  E D I T O R
Acute systemic reactions to sublingual immunotherapy for 
house dust mite
To the Editor,
Sublingual immunotherapy (SLIT) is a successful treatment of allergic 
rhinoconjunctivis by inducing clinical and immunological tolerance.1 
Compared to subcutaneous immunotherapy (SCIT), severe adverse 
reactions to SLIT are less frequently seen.2 In 2017, treatment with 
SQ house dust mite sublingual immunotherapy tablets (hereinafter: 
SQ-HDM) has been registered in many European countries. In this 
letter, we describe two patients with acute systemic adverse reac-
tions after administration of SQ-HDM. See Table 1 for patient char-
acteristics. Both events occurred in our outpatient clinic.
Patient 1 was a 35-year-old female with persistent allergic 
rhinoconjunctivitis due to HDM allergy, which was serologically 
confirmed (Table 1). Furthermore, she was known to suffer from 
moderate allergic asthma, well controlled with fluticasone/salme-
terol (Seretide 250/25 µg/dose b.i.d.) and salbutamol inhalations 
(Salbutamol 100 µg/dose if necessary q.i.d.) without airflow ob-
struction (see pulmonary function testing in Table 1). Due to uncon-
trolled allergic rhinitis, despite nasal corticosteroids (Azelastine/
Fluticasone Nasal Spray 137/50 µg per actuation) and antihista-
mines (Levocetirizine 5 mg b.i.d.), immunotherapy with SQ-HDM 
was initiated. She never had treatment with SCIT previously. She 
received her first treatment with SQ-HDM in September. At the 
time of administration, routine questioning confirmed that she was 
in a good clinical condition without any signs of current infections, 
respiratory tract symptoms, oral lesions, emotional stress, or sleep 
deprivation and the administration of SQ-HDM was not during her 
menstrual period. Within 5 minutes after sublingual administration 
of SQ-HDM, she experienced dizziness, shortness of breath, and 
feeling of thick throat. Examination showed a blood pressure of 
161/88 mmHg, a tachycardia of 150 beats per minute (an electro-
cardiogram showed sinus tachycardia without other abnormalities). 
Her temperature was 37.2°C, oxygen saturation of 100% without 
oxygen therapy, and she was breathing 16 times per minute. There 
were no signs of urticaria, and no swelling of the tongue or lips was 
observed (nasopharyngoscopy was not performed). Diffuse muscle 
fasciculations were observed without signs of rough myoclonus. She 
was stabilized and treated with adrenalin 0.5 mg intramuscularly 
and clemastine 2 mg intravenously. After treatment, the symptoms 
disappeared within an hour. She was admitted for a short period 
of observation. Serum tryptase level 1-2 hours after the event was 
3.30 µg/L (ref: 0.00-11.4).
Patient 2 was a 19-year-old female with refractory rhinocon-
junctivitis with allergy to tree pollen, grass pollen, and HDM, con-
firmed serologically (Table 1) as well as by a skin prick test. She 
declined SCIT; therefore, treatment with SQ-HDM was initiated 
in September. She has not been treated with immunotherapy in 
the past. She confirmed specifically that she was in a good clinical 
condition without any signs of current infections, respiratory tract 
symptoms, oral lesions, emotional stress, or sleep deprivation, and 
the administration of SQ-HDM was not during her menstrual period. 
Within 3 minutes after sublingual administration, she experienced a 
feeling of thick throat, shortness of breath, dizziness, and excessive 
vomiting. Her vital signs showed a blood pressure of 109/86 mmHg, 
a tachycardia of 96 per minute, and oxygen saturation of 96% with-
out oxygen therapy, and she was breathing 16 times per minute. She 
was stabilized and treated with adrenalin 0.5 mg and clemastine 2 
mg intramuscularly. Serum tryptase level measured 1-2 hours after 
reaction was 4.90 µg/L (ref: 0.00-11.4). After 4 hours of observation, 
she was discharged in a good condition.
Acute severe adverse reactions to SQ-HDM have been described 
sporadically.3 To our best knowledge, only 1 case of anaphylaxis to 
SQ-HDM and 4 cases of systemic reactions to grass SLIT have been 
reported.3,4 However, physicians need to be aware of these reac-
tions and should be able to stabilize a patient with an acute reaction.
Both patients showed symptoms of a systemic reaction which 
occurred immediately after sublingual administration of SQ-HDM. 
According to the World Allergy Organization (WAO) systemic aller-
gic reaction grading system, both patients had a grading score of 
3.5,6 Even though grade 3 is not defined as anaphylaxis by WAO, 
anaphylaxis cannot be ruled out, because this is a clinical diagnosis. 
The observation that serum tryptase 1 to 2 hours after the start of 
the reactions was low, does not exclude an IgE-mediated reaction.7
Several risk factors have been described for developing sys-
temic reactions, such as decreased lung function, oral lesions, con-
current infections, or emotional stress.8 In our patients, none of 
these risk factors could be identified. Patient 1 was known with 
rhinoconjunctivitis and moderate asthma without signs of obstruc-
tion. Patient 2 only suffered from rhinoconjunctivitis and did not 
have symptoms of asthma. Both patients were positive for Der p2 
and Der f2, but further extended molecular sensitization profile of 
HDM and pollens in both patients was different. The administration 
of SLIT took place in the month September. In autumn, exposure to 
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HDM in the Netherlands is higher than in spring.9 However, there 
are no studies showing that the onset of immunotherapy adminis-
tration with HDM should be determined by seasonal variation in 
HDM exposure.
In conclusion, acute systemic reactions to SQ-HDM may occur. 
Awareness is important, and patients should be monitored appropri-
ately after taking SQ-HDM.
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TA B L E  1   Patient characteristics
Patient 1 Patient 2
Gender Female Female
Age 35 19
Medical history Well-controlled moderate asthma
Allergic rhinoconjunctivitis due to 
house dust mite (HDM)
Eczema
Allergic rhinoconjunctivitis due to HDM, tree pollens, 
and grass pollens
Lung function VC: 3,48 liter (91% of predicted), FEV1: 
2,79 liter (88% of predicted), FEV1/
VC: 80%, DLCO: 78% of predicted, 
DLCO/VA: 84%
NA
Skin prick test NA Positive for HDM, tree pollens, grass pollens, and cat.
Serological test Reference kU/L: < 0.35
Reference ISU-E: < 0.30
HDM 1.64 kU/L
Der f2 1.90 ISU-E
Der p2 1.70 ISU-E
Der p23 1.0 ISU-E
HDM 30.0 kU/L
Der f2 23.70 kU/L
Der f1 17.10 kU/L
Der p1 10.20 kU/L
Der p2 23.50 kU/L
Birch pollens 48.30 kU/L
Hazel pollens 15.90 kU/L
Alder pollens 45.70 kU/L
Oak pollens 12.20 kU/L
Rye pollens 19.40 kU/L
Timothy grass 25.10 kU/L
Bermuda grass 35.50 kU/L
Sweet vernal grass 30.00 kU/L
Medication Levocetirizine 5 mg b.i.d.
Azelastine/fluticasone nasal spray 




100 µg/dose if necessary q.i.d.
Fluticasone furoate 27,6ug q.d.
Levocetirizine 5 mg b.i.d.
Symptoms during acute reaction to 
SQ-HDM
Dizziness, tachycardia, feeling of thick 
throat, dyspnea
Itchy mouth, dizziness, feeling of thick throat, dyspnea, 
excessive vomiting.
Hemodynamics Blood pressure: 161/88 mmHg
Pulse: 150 beats/min
Temperature: 37.2°C
Saturation: 100% without oxygen 
therapy
Breathing: 16 times/min
Blood pressure: 109/86 mmHg
Pulse: 96 beats/min
Saturation: 96% without oxygen therapy
Breathing: 16 times/min.
Treatment Adrenalin 0.5 mg IM
Clemastine 2 mg IV
Adrenalin 0.5 mg IM
Clemastine 2 mg IV
Serum tryptase 1-2 h after reaction 3.30 µg/L (ref: 0.00-11.4) 4.90 µg/L (ref: 0.00 - 11.4)
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